[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331584-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331584-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","value-of-mri-t2-mapping-to-differentiate-clinically-significant-prostate-cancer","Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer","","Standardized reporting of multiparametric prostate MRI (mpMRI) using international standards is widespread, yet quantitative measurements are not easily comparable. Although T2 mapping sequences can produce repeatable quantitative biomarkers, they are often too time-consuming for routine use. This retrospective single-center study assessed a highly accelerated T2 mapping research sequence to separate benign from malignant lesions using biopsy-confirmed outcomes and REML-based linear mixed-effects modeling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/value-of-mri-t2-mapping-to-differentiate-clinically-significant-prostate-cancer/331584/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/value-of-mri-t2-mapping-to-differentiate-clinically-significant-prostate-cancer/331584.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To evaluate whether quantitative measurements from a highly accelerated T2 mapping sequence can differentiate benign from malignant prostate lesions using a clinically usable threshold.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and reference standards defined?",{"text":68,"@type":64},"The retrospective single-center study included 54 prostate patients with MRI indicated clinically and biopsy-confirmed carcinoma or exclusion of carcinoma, using standard-of-care biopsy results as the reference.",{"name":70,"@type":61,"acceptedAnswer":71},"What threshold was suggested for differentiating malignant lesions?",{"text":72,"@type":64},"A cut-off value of 109.2 ms for mean T2 was suggested to distinguish malignant from non-malignant prostate regions, with clear separation in the peripheral zone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331584,1790103952,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Journal of Imaging Informatics in Medicine (2024) 37:3304–3315  \n[https://doi.org/10.1007/s10278-024-01](https://doi.org/10.1007/s10278-024-01)150-6  \nValue of MRI ‑ T2 Mapping to Differentiate Clinically Significant Prostate Cancer  \nAndreas Michael Bucher1 · Jan Egger2 · Julia Dietz1 · Ralph Strecker3 · Tom Hilbert4,5,6 · Eric Frodl1 · Mike Wenzel7 · Tobias Penzkofer8,10 · Bernd Hamm8 · Felix KH Chun7 · Thomas Vogl1 · Jens Kleesiek11,12,13,14,15 · Martin Beeres1,9  \nReceived: 16 November 2023 / Revised: 21 May 2024 / Accepted: 23 May 2024 / Published online: 26 June 2024 © The Author(s) 2024  \nAbstract  \nStandardized reporting of multiparametric prostate MRI (mpMRI) is widespread and follows international standards (PiRADS) . However, quantitative measurements from mpMRI are not widely comparable. Although T2 mapping sequences can provide repeatable quantitative image measurements and extract reliable imaging biomarkers from mpMRI, they are often time-consuming. We therefore investigated the value of quantitative measurements on a highly accelerated T2 mapping sequence, in order to establish a threshold to differentiate benign from malignant lesions. For this purpose, we evaluated a novel, highly accelerated T2 mapping research sequence that enables high-resolution image acquisition with short acquisition times in everyday clinical practice. In this retrospective single-center study, we included 54 patients with clinically indicated MRI of the prostate and biopsy-confirmed carcinoma (n = 37) or exclusion of carcinoma (n = 17). All patients had received a standard of care biopsy of the prostate, results of which were used to confirm or exclude presence of malignant lesions. We used the linear mixed-effects model-fit by REML to determine the difference between mean values of cancerous tissue and healthy tissue. We found good differentiation between malignant lesions and normal appearing tissue in the peripheral zone based on the mean T2 value. Specifically, the mean T2 value for tissue without malignant lesions was (151.7 ms [95% CI: 146.9–156.5 ms] compared to 80.9 ms for malignant lesions [95% CI: 67.9–79.1 ms]; p \u003C 0.001) . Based on this assessment, a limit of 109.2 ms is suggested. Aditionally, a significant correlation was observed between T2 values of the peripheral zone and PI-RADS scores (p = 0.0194) . However, no correlation was found between the Gleason Score and the T2 relaxation time. Using REML, we found a difference of-82.7 ms in mean values between cancerous tissue and healthy tissue. We established a cut-off-value of 109.2 ms to accurately differentiate between malignant and non-malignant prostate regions. The addition of T2 mapping sequences to routine imaging could benefit automated lesion detection and facilitate contrastfree multiparametric MRI of the prostate.  \nKeywords Multiparametric prostate MRI · T2 mapping · Prostate cancer · Quantitative imaging  \nShort Synopsis In this investigation, we found a good correlation between quantitative T2 mapping measurements of the prostate in 36 prostate cancer patients and biopsy results. Malignant lesions exhibited a significant reduction in T2  \nrelaxation time (151 .7 ms [95% CI: 160.4–143.6 ms] vs. 80.9 ms [95% CI: 78.2–60.4 ms]) . The linear mixed-effects model, fitted by REML (R Statistics), revealed a difference of-82.7 ms and-42.8 ms for average and minimum values, respectively, between cancerous and healthy tissue.  \nExtended author information available on the last page of the article  \nIntroduction  \nProstate cancer (pCA) is the second most common solid tumor in men worldwide and has the highest age-standardized rate (ASR) in Northern Europe at 83 per 100,000 . The lifetime cumulative risk to develop a pCA is 3.9%[1] .  \nMultiparametric MRI (mpMRI) is the preferred imaging modality for prostate cancer and includes T1-weighted, T2-weighted (T2w), diffusion-weighted (DWI), and dynamic contrast-enhanced (DCE) sequences [2, 3] . MpMRI complements digital rect","cbCaijMJV9CAOZPY","https://ap.wps.com/l/cbCaijMJV9CAOZPY","pdf",1970051,12,"English","# Abstract\n## Introduction\n## Methods and study design\n## Results and threshold setting\n## Correlations with PI-RADS and Gleason score","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To evaluate whether quantitative measurements from a highly accelerated T2 mapping sequence can differentiate benign from malignant prostate lesions using a clinically usable threshold.\"},{\"question\":\"How were patients and reference standards defined?\",\"answer\":\"The retrospective single-center study included 54 prostate patients with MRI indicated clinically and biopsy-confirmed carcinoma or exclusion of carcinoma, using standard-of-care biopsy results as the reference.\"},{\"question\":\"What threshold was suggested for differentiating malignant lesions?\",\"answer\":\"A cut-off value of 109.2 ms for mean T2 was suggested to distinguish malignant from non-malignant prostate regions, with clear separation in the peripheral zone.\"}]","Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer | PDF",1789994192]